Redmile Group
Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.
Business Model:
Revenue: $15.9M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Redmile Group Information
Geographic Data
Address: 1 Letterman Dr
City: San Francisco
State: CA
Zip: 94129
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$472M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2020 | Lifesprout | Series A | 0 |
| 11/2020 | MedAvail | Series E | 0 |
| 9/2016 | Array BioPharma | Post-IPO Equity | 1.4M |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 5/2022 | Rapt Therapeutics | PIPE | 50M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 3/2021 | Amunix | Series B | 117M |
| 11/2021 | Home Biosciences | Seed | 15M |
| 6/2018 | Gritstone Bio | Series C | 21M |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2021 | Thriveworks | Venture Round | - |
| 6/2019 | Saluda Medical | Venture Round | 0 |
| 1/2018 | BioNTech | Series A | 270M |
| 7/2019 | BioNTech | Series B | 0 |
| 4/2011 | Oxford Nanopore Technologies | Venture Round | 41.2M |
| 11/2013 | inui Health | Series A | 10.5M |
| 12/2013 | Invitae | Series E | 0 |
| 12/2016 | Augmedix | Venture Round | 23M |
| 3/2021 | OncoResponse | Series C | 0 |
| 10/2017 | ADC Therapeutics | Series E | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 7/2008 | PacBio | Series E | 100M |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 9/2017 | Call9, Inc. | Series B | 24M |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 5/2021 | HydraFacial | Post-IPO Equity | 0 |
| 9/2018 | Evox Therapeutics | Series B | 0 |
| 1/2019 | Science 37 | Series D | 0 |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 7/2015 | Afferent Pharmaceuticals | Series C | 55M |
| 9/2018 | Vapotherm | Series D | 0 |
| 11/2022 | Escient Pharmaceuticals | Series C | 120M |
| 12/2019 | ArcherDX | Series C | 0 |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 1/2021 | Genalyte | Venture Round | 0 |
| 6/2017 | Nightstar Therapeutics | Series C | 45M |
| 5/2019 | ElevateBio | Series A | 150M |
| 6/2021 | Strand Therapeutics | Series A | 52M |
| 8/2019 | Stereotaxis | Post-IPO Equity | 25M |
| 1/2021 | Impulse Dynamics | Series D | 60M |
| 2/2021 | Excision BioTherapeutics | Series A | - |
| 1/2018 | Scholar Rock | Series C | 47M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 8/2017 | aTyr Pharma | Post-IPO Equity | 45M |
| 6/2022 | Scholar Rock | Post-IPO Equity | 0 |
| 12/2014 | Scioderm | Series B | 20M |
| 9/2017 | Replimune Group | Series B | 55M |
| 9/2018 | Atreca | Series C | 125M |
| 3/2020 | ElevateBio | Series B | 170M |
| 9/2018 | OncoResponse | Series B | 40M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 11/2013 | Innate Pharma | Post-IPO Equity | 27.3M |
| 11/2016 | Genalyte | Series D | 36M |
| 2/2021 | Ayala Pharmaceuticals | Private Placement | 25M |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
| 2/2021 | Evox Therapeutics | Series C | 96.7M |
| 3/2020 | Redx Pharma | Post-IPO Equity | 33.6M |
| 3/2022 | Saluda Medical | Equity | 125M |
| 1/2021 | Verve Therapeutics | Series B | 94M |
| 5/2018 | Attenua | Series A | 35M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 2/2019 | Hookipa Pharma | Series D | 37.4M |
| 1/2020 | Sonendo | Venture Round | 85M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 5/2017 | Xeris Pharmaceuticals | Series C | 0 |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 12/2020 | SomaLogic | Series A | 0 |
| 1/2019 | Cabaletta Bio | Series B | 0 |
| 9/2021 | Attralus | Series B | 116M |
| 10/2016 | Science 37 | Series B | 31M |
| 12/2017 | Allakos | Series B | 100M |
| 2/2016 | Yumanity Therapeutics | Series A | 51M |
| 11/2015 | First Aid Shot Therapy | Series C | 24M |
| 10/2014 | MedAvail | Series C | 0 |
| 7/2018 | MedAvail | Series D | 0 |
| 8/2022 | Kymera Therapeutics | Post-IPO Equity | 150M |
| 2/2014 | First Aid Shot Therapy | Series B | 7M |
| 7/2019 | IGM Biosciences | Series C | 102M |
| 1/2016 | Syros Pharmaceuticals | Series C | 40M |
| 12/2020 | Neuron23 | Series B | 80M |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 6/2019 | ADC Therapeutics | Series E | 0 |
| 10/2019 | Augmedix | Series B | 0 |
| 3/2021 | Entrada Therapeutics | Series B | 0 |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 4/2016 | Augmedix | Venture Round | 0 |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 5/2020 | Atea | Series D | 215M |
| 6/2020 | Shattuck Labs | Series B | 0 |
| 3/2021 | ElevateBio | Series C | 525M |
| 3/2020 | Amunix | Series A | 0 |
| 10/2014 | Invitae | Series F | 0 |
| 5/2019 | AlloVir | Series B | 120M |
| 2/2019 | Neurogene | Series A | 68.5M |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 6/2012 | TriVascular | Series D | 60M |
| 3/2018 | TCR2 | Series B | 0 |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 10/2014 | Syros Pharmaceuticals | Series B | 53M |
| 5/2023 | ElevateBio | Series D | 0 |
| 7/2022 | AlloVir | Post-IPO Equity | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 9/2012 | Foundation Medicine | Series B | 42.5M |
| 3/2022 | Neuron23 | Series C | 0 |
| 11/2018 | Aprea | Series C | 0 |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
| 12/2020 | RayzeBio | Series B | 105M |
| 3/2017 | Virta Health | Equity | 37M |
| 11/2021 | GRO Biosciences | Series A | 25M |
| 5/2020 | Clear Labs | Venture Round | 21M |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 3/2020 | Kymera Therapeutics | Series C | 102M |
| 5/2021 | Clear Labs | Series C | 60M |
| 4/2017 | Science 37 | Series C | 35M |
| 4/2014 | One Medical | Private Equity Round | 40M |
| 8/2015 | Genalyte | Series C | 0 |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 5/2017 | Vapotherm | Series D | 0 |
| 8/2015 | Wave Life Sciences | Series B | 66M |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 7/2021 | Prime Medicine | Series B | 200M |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 11/2021 | The Oncology Institute of Hope and Innovation | Post-IPO Equity | 275M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 3/2021 | AgomAb Therapeutics | Series B | 0 |
| 8/2020 | Science 37 | Venture Round | 0 |
| 4/2021 | Ceribell | Series C | 53M |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 4/2021 | Boundless Bio | Series B | 105M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 4/2021 | Adagio Therapeutics | Series C | 0 |
| 9/2021 | Mammoth Biosciences | Series D | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 6/2021 | RayzeBio | Series C | 108M |
| 5/2020 | CorVent Medical | Seed Round | 0 |
| 11/2013 | TriVascular | Series E | 0 |
| 4/2014 | Adverum Biotechnologies | Series B | 55M |
| 3/2021 | Absci | Venture Round | 0 |
| 11/2020 | Mammoth Biosciences | Series C | 45M |
| 1/2016 | Xeris Pharmaceuticals | Series C | 41M |
| 10/2021 | Sphere Fluidics | Venture Round | 41.4M |
| 7/2020 | Annexon Biosciences | Series C | 100M |
| 10/2020 | Absci | Series E | 70M |
| 4/2015 | inui Health | Series B | 35M |
| 1/2018 | Alder Biopharmaceuticals | Post-IPO Equity | 250M |
| 7/2022 | AlloVir | Post-IPO Equity | 0 |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 6/2022 | Scholar Rock | Post-IPO Equity | 0 |
| 5/2022 | Rapt Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | Saluda Medical | Private Equity Round | 0 |
| 2/2022 | Star Therapeutics | Venture Round | 0 |
| 2/2022 | Electra Therapeutics | Series B | 0 |
| 11/2021 | The Oncology Institute of Hope and Innovation | Post-IPO Equity | 0 |
| 11/2021 | Home Biosciences | Seed Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
